BETHESDA, Md., July 22Contributing membership in The Biomarkers Consortium now totals 30 companies and non-profit trade associations and advocacy groups, it was announced today. To date, these organizations have committed an aggregate of nearly $2 million to fund the first year of the central activities of the consortium which is managed be the Foundation for the National Institutes of Health.
A major public-private biomedical research partnership unprecedented in breadth, The Biomarkers Consortium embraces government, industry, patient advocacy and other non-profit private sector organizations. In addition to the Foundation for NIH, founding members include: the National Institutes of Health, the Food and Drug Administration, and the Pharmaceutical Research and Manufacturers of America.
The 30 contributing members are: the Academy of Molecular Imaging; the Advanced Medical Technology Association; the Alzheimers Association; the American Association for Cancer Research; the American Cancer Society; the American College of Neuropsychopharmacology; the American Society of Clinical Oncology; the Association of Clinical Research Organizations; AstraZeneca; BG Medicine; the Biotechnology Industry Organization; Boehringer-Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; EMD Serono; the Michael J. Fox Foundation for Parkinsons Research; GlaxoSmithKline; GVK BIOSciences; Johnson & Johnson, the Kidney Cancer Association; The Leukemia & Lymphoma Society; Eli Lilly & Company; Luminex Corporation; Merck & Co., Inc.; Novartis; Novo Nordisk; Pfizer Inc; the Pharmaceutical Research and Manufacturers of America; the Radiological Society of North America; F. Hoffmann-La Roche; and, the Society of Nuclear Medicine.
As previously reported, this large-scale, public-private biomedical research partnership was formally launched in late 2006 to identify and qualify new, quantitative biological markers (biomarkers), for use by biomedica
Contact: Charles Pucie
NIH/Foundation for the National Institutes of Health